EXPLORE CONNECTIONS
The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide
Follow the relationships that help you find your next source.
Connections are not prepared for this record yet, or its source metadata has changed. The original record remains available while background snapshots are rebuilt.